X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Zelsuvmi (berdazimer topical gel, 10.3%) is a nitric oxide (NO) releasing agent which is approved for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Zelsuvmi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
The partnership aims to accelerate Phase 3 development of Qtorin™ rapamycin for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).
Lead Product(s): Sirolimus
Therapeutic Area: Rare Diseases and Disorders Product Name: Qtorin
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Palvella Therapeutics
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Partnership December 01, 2023
Details:
Through the acquisition, Ligand acquires royalty on Sanofi’s Tzield (teplizumab-mzwv), the first disease-modifying therapy in type 1 diabetes and a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and children aged 8 years and older with Stage 2 T1D.
Lead Product(s): Teplizumab-mzwv
Therapeutic Area: Endocrinology Product Name: Tzield
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Tolerance Therapeutics
Deal Size: $20.0 million Upfront Cash: $20.0 million
Deal Type: Acquisition November 01, 2023
Details:
Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of TAK-935 (soticlestat), being developed by Takeda in two Phase 3 trials for Lennox-Gastaut syndrome and Dravet syndrome.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Ovid Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 18, 2023
Details:
Through the acquisition, Ligand will gain access to all the assets of Novan, including SB206 (berdazimer sodium gel), all other programs in development, the NITRICIL™ drug delivery technology, and the commercial assets of its EPI health business.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Novan
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Divestment September 27, 2023
Details:
Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with IgAN. It is being investigated for focal segmental glomerulosclerosis.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Travere Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
V116 is an investigational, 21-valent pneumococcal conjugate vaccine in Phase 3 development for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population.
Lead Product(s): 21-Valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: V116
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Through the acquisition, Ligand will gain access to all the assets of Novan, including SB206 (berdazimer sodium gel), all other programs in development, the NITRICIL™ drug delivery technology, and the commercial assets of its EPI health business.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Novan
Deal Size: $15.0 million Upfront Cash: $15.0 million
Deal Type: Acquisition July 17, 2023
Details:
SB206 (berdazimer sodium), the active ingredient in berdazimer gel, 10.3% (SB206), is a new chemical entity, for the treatment of molluscum contagiosum is a potential first-in-class topical nitric oxide-releasing agent with positive Phase 3 data submitted to the FDA.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
For the last decade, Ligand has been focused on providing the tools and technologies needed by the pharmaceutical industry and sharing in the promise of drug innovation with the shareholders.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: OmniAb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Demerger November 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
